Arcutis Biotherapeutics (ARQT) Stock Forecast & Price Target

Arcutis Biotherapeutics is expected to have a positive cash flow in the remainder of 2026 and beyond, with a net loss of $11.3 million in the first quarter of 2026 and cash reserves of approximately $224 million. Despite seasonal headwinds in the first quarter, their product Zoryve showed a strong performance with $105.4 million in sales, and is expected to bounce back in the second quarter with increased sales due to higher Rx volumes and improved GTNs. The company also plans to expand its sales force and increase access to Medicaid and Medicare, which will likely drive further growth in the second half of 2026. However, there is a potential risk in the form of competition from generic topical products and recently approved Vtama. The company will assume responsibility for the sales of Zoryve in the PCP and pediatric settings, which is not expected to negatively impact their sales guidance of $455 million to $470 million for 2026.

Arcutis Biotherapeutics is facing several significant risks in its strategy for developing and commercializing treatments for dermatological diseases. The company is heavily dependent on the success of its product candidate ZORYVE and its ability to gain market share in a competitive landscape with generic topical products and recently approved competitors. Additionally, the termination of their co-promotion agreement with Kowa Pharmaceuticals may negatively affect their cash flow and net product sales guidance for 2026. There is also a development and regulatory risk, as the success of Zoryve is dependent on FDA approvals for different indications, and it still requires approval for scalp psoriasis.